8-K: Axsome Therapeutics Reports Strong First Quarter Growth and Pipeline Progress

Axsome Therapeutics announced a 160% year-over-year increase in total net product revenue for the first quarter of 2024, driven by strong sales of Auvelity and Sunosi, and provided updates on its clinical pipeline.

Summary

• Axsome Therapeutics reported a total net product revenue of $75.0 million for the first quarter of 2024, a 160% increase compared to the same period in 2023.
• Auvelity net product sales reached $53.4 million, showing a 240% year-over-year growth.
• Sunosi net product revenue was $21.6 million, representing a 64% year-over-year increase.
• The company's research and development expenses increased to $36.8 million, up from $17.8 million in the first quarter of 2023, due to ongoing clinical trials and manufacturing costs.
• Selling, general, and administrative expenses rose to $99.0 million, compared to $74.2 million in the prior year, primarily due to commercialization activities.
• Axsome reported a net loss of $68.4 million, or $(1.44) per share, for the first quarter of 2024, compared to a net loss of $11.2 million, or $(0.26) per share, for the same period in 2023.
• The company's cash and cash equivalents totaled $331.4 million as of March 31, 2024.
• Axsome believes its current cash is sufficient to fund operations into cash flow positivity.
• Approximately 95,000 prescriptions were written for Auvelity in the first quarter of 2024, a 12% sequential increase from the previous quarter.
• Payer coverage for Auvelity is stable at approximately 70% of all covered lives.
• Approximately 42,000 prescriptions were written for Sunosi in the U.S. in the first quarter of 2024, a 1.6% decrease compared to the fourth quarter of 2023.
• Axsome is advancing its pipeline with multiple Phase 3 trials, including AXS-05 for Alzheimer's disease agitation, AXS-12 for narcolepsy, and solriamfetol for ADHD, MDD, and BED.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there is strong revenue growth and pipeline progress, the significant increase in net loss and operating expenses tempers the positive aspects. The company's cash position is adequate, but the path to profitability is still uncertain.

Positives

• Axsome experienced significant revenue growth in the first quarter of 2024, driven by strong sales of Auvelity and Sunosi.
• Auvelity sales showed a substantial 240% year-over-year increase, indicating strong market adoption.
• Sunosi also demonstrated solid growth with a 64% year-over-year increase in revenue.
• The company secured a second large GPO contract for Auvelity, which should expand its market reach.
• Positive Phase 3 results for AXS-12 in narcolepsy were announced, moving the drug closer to market approval.
• Axsome initiated multiple Phase 3 trials for solriamfetol, expanding its pipeline.
• The company is on track to resubmit the NDA for AXS-07 and submit the NDA for AXS-14 in the second quarter of 2024.
• Axsome's cash position is considered sufficient to fund operations into cash flow positivity.

Negatives

• The company reported a net loss of $68.4 million for the first quarter of 2024, significantly higher than the $11.2 million loss in the same period of 2023.
• Research and development expenses increased substantially to $36.8 million, reflecting the cost of ongoing clinical trials.
• Selling, general, and administrative expenses also increased to $99.0 million, driven by commercialization efforts.
• Sunosi prescription volume decreased slightly by 1.6% compared to the previous quarter.

Risks

• The company's increased operating expenses, particularly in R&D and SG&A, contributed to a significant net loss.
• The success of the company's pipeline depends on positive clinical trial results and regulatory approvals.
• The company's ability to achieve cash flow positivity is dependent on continued revenue growth and cost management.
• There are risks associated with the commercialization of new products and market acceptance.
• The company's forward-looking statements are subject to various risks and uncertainties, including regulatory approvals and market conditions.

Future Outlook

Axsome believes its current cash is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan. The company anticipates several key milestones in the coming months, including NDA submissions and topline results from multiple Phase 3 trials.

Management Comments

• The first quarter was marked by strong financial performance for our on-market products which are delivering important and differentiated treatment options for patients living with depression, narcolepsy and obstructive sleep apnea, said Herriot Tabuteau, MD, CEO of Axsome Therapeutics.
• We also significantly advanced our innovative neuroscience pipeline in the quarter.
• We announced positive Phase 3 results for AXS-12 in narcolepsy, a major step toward making this new medicine available to patients living with this debilitating condition, and we launched two pivotal trials of solriamfetol in major depressive disorder and binge eating disorder.
• In the coming months we look forward to resubmitting our NDA for AXS-07 in migraine, and to submitting our NDA for AXS-14 in fibromyalgia.

Industry Context

Axsome's focus on central nervous system (CNS) disorders aligns with the growing need for innovative treatments in this area. The company's pipeline includes multiple late-stage product candidates targeting conditions with limited treatment options, positioning it to potentially capture a significant share of the market. The positive results for AXS-12 in narcolepsy and the initiation of Phase 3 trials for solriamfetol in MDD and BED demonstrate the company's commitment to addressing unmet needs in the CNS space.

Comparison to Industry Standards

• Axsome's 240% year-over-year growth in Auvelity sales is significantly higher than the average growth rate for pharmaceutical products in the CNS market, suggesting strong market uptake.
• The company's R&D spending of $36.8 million in Q1 2024 is substantial, reflecting its commitment to advancing its pipeline, which is comparable to other biotech companies focused on late-stage clinical development.
• The net loss of $68.4 million is higher than some peers, but this is typical for companies investing heavily in clinical trials and commercialization efforts.
• The company's cash position of $331.4 million is adequate to fund its operations into cash flow positivity, which is a positive sign compared to companies with limited cash reserves.
• The successful contracting with two of the three largest GPOs for Auvelity is a positive development, as it indicates a strong potential for market access and coverage, which is a key factor for commercial success in the pharmaceutical industry.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss, but encouraged by the strong revenue growth and pipeline progress.
• Employees may benefit from the company's growth and expansion, but may also face increased pressure to meet targets.
• Patients may benefit from the development of new treatment options for CNS disorders.
• Customers (physicians and pharmacies) may see increased availability of Axsome's products.
• Suppliers may see increased demand for their products and services.
• Creditors may be reassured by the company's cash position and revenue growth.

Next Steps

• Axsome will resubmit the NDA for AXS-07 in migraine and submit the NDA for AXS-14 in fibromyalgia in the second quarter of 2024.
• The company will continue enrollment in the ACCORD-2 trial of AXS-05 for Alzheimer's disease agitation, with completion expected mid-year 2024.
• Axsome will initiate a Phase 3 trial of solriamfetol in shift work disorder in the second quarter of 2024.
• The company anticipates topline results from several Phase 3 trials in the second half of 2024, including ADVANCE-2, EMERGE, FOCUS, and the open-label safety extension trial of AXS-12.
• Axsome plans to initiate a pivotal Phase 2/3 trial of AXS-05 for smoking cessation in 2024.
• The company expects topline results from the PARADIGM and ENGAGE trials of solriamfetol in 2025.

Key Dates

Keywords

Axsome Therapeutics, Auvelity, Sunosi, AXS-05, AXS-12, AXS-07, AXS-14, solriamfetol, narcolepsy, Alzheimer's disease agitation, migraine, fibromyalgia, ADHD, major depressive disorder, binge eating disorder, clinical trials, NDA, GPO, CNS disorders